OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press27710.17650/1818-8346-2018-13-1-63-72DIAGNOSIS OF HEMATOLOGIC MALIGNANCIESДИАГНОСТИКА ГЕМОБЛАСТОЗОВMULTICOLOR FLOW CYTOMETRY AS A DIAGNOSTIC TOOL IN MYELODYSPLASTIC SYNDROMESРОЛЬ МНОГОЦВЕТНОЙ ПРОТОЧНОЙ ЦИТОФЛУОРИМЕТРИИ В ДИАГНОСТИКЕ МИЕЛОДИСПЛАСТИЧЕСКИХ СИНДРОМОВhttps://orcid.org/0000-0001-5932-0285DavydovaYu. O.ДавыдоваЮ. О.
Russian Federation

4 Novyi Zykovskiy proezd, 125167 Moscow

 Давыдова Юлия Олеговна

125167 Москва, Новый Зыковский проезд, 4

juliya89mur@yandex.ruGaltsevaI. V.ГальцеваИ. В.
Russian Federation

4 Novyi Zykovskiy proezd, 125167 Moscow

125167 Москва, Новый Зыковский проезд, 4

KokhnoA. V.КохноА. В.
Russian Federation

4 Novyi Zykovskiy proezd, 125167 Moscow

125167 Москва, Новый Зыковский проезд, 4

ParovichnikovaЕ. N.ПаровичниковаЕ. Н.
Russian Federation

4 Novyi Zykovskiy proezd, 125167 Moscow

125167 Москва, Новый Зыковский проезд, 4

National Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России1105201813163721105201811052018https://oncohematology.abvpress.ru/ongm/article/view/277

Myelodysplastic syndromes (MDS) are heterogeneous group of clonal hematological neoplasms characterized by cytopenias, sighs of dysplasia and high risk of transformation in acute myeloid leukemia. Diagnostics of MDS requires a comprehensive approach, but even when performing cytological, cytogenetic, molecular and histological studies, it is not always possible to establish a diagnosis. Multicolor flow cytometry (MFC) is a high-tech method, increasingly used in the diagnosis of various hematologic diseases. Over the last years, MFC is standardized for assessing of dysplasia in all cell compartments of the bone marrow. Many research groups have demonstrated high sensitivity and specificity of this diagnostic approach, which indicates the necessity of integration of flow cytometric study into diagnostic protocols of MDS.

Миелодиспластические синдромы (МДС) – гетерогенная группа клональных заболеваний системы кроветворения, характеризуемых цитопениями, признаками дисмиелопоэза, высокой частотой аномалий кариотипа и риском трансформации в острые миелоидные лейкозы. Диагностика МДС требует комплексного подхода, но даже при выполнении цитологического, цитохимического, цитогенетического, молекулярно-генетического и гистологического исследований не всегда удается подтвердить диагноз. Многоцветная проточная цитофлуориметрия (МПЦ) – высокотехнологичный метод, часто применяемый в диагностике различных гематологических заболеваний. В течение последних лет активно проводится стандартизация МПЦ для оценки дисплазии во всех ростках кроветворения при МДС. Многими исследовательскими группами были продемонстрированы высокие показатели чувствительности и специфичности этого метода, что свидетельствует о необходимости интеграции МПЦ в диагностические протоколы МДС.

myelodysplastic syndromesflow cytometryimmunophenotypingdiagnostic toolsмиелодиспластические синдромыпроточная цитофлуориметрияиммунофенотипированиелабораторная диагностикаSavchenko V. G., Parovichnikova E. N., Kokhno A. V. et al. National clinical guidelines for the diagnosis and treatment of adult myelodysplastic syndromes (2015). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1S(4)):1–32 (In Russ.). DOI: 10.18821/0234‑5730‑2016‑61‑1.Савченко В. Г., Паровичникова Е. Н., Кохно А. В. и др. Национальные клинические рекомендации по диагностике и лечению миелодиспластических синдромов взрослых (2015 г.). Гематология и трансфузиология 2016;61(1S(4)):1–32.Tefferi A., Vardiman J. W. Myelodysplastic Syndromes. N Engl J Med 2009;361(19):1872–85. DOI: 10.1056/NEJMra0902908. PMID: 19890130.Dvirnyk V. N., Kokhno A. V., Parovichnikova E. N. Secondary dysmyelopoiesis in patients with myelodysplastic syndromes. Terapevticheskiy arkhiv = Therapeutic archive 2014;86(7):97–103 (In Russ.). PMID: 25314785.Двирнык В. Н., Кохно А. В., Паровичникова Е. Н. Вторичный дисмиелопоэз у больных миелодиспластическими синдромами. Терапевтический архив 2014;86(7):97–103.Cremers E. M.P., Westers T. M., Alhan C. et al. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from nonneoplastic cytopenias. Eur J Cancer 2016;54:49–56. DOI:10.1016/j.ejca.2015.11.013.PMID: 26720403.Soenen V., Preudhomme C., Roumier C. et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998;91(3):1008–15. PMID: 9446663.Kovrigina A. M., Glinkina S. A., Baykov V. V. Principles of pathomorphological differential diagnosis of myelodysplastic syndromes. Klinicheskaya onkogematologiya = Clinical oncohematology 2015;8(1):62–8 (In Russ.).Ковригина А. М., Глинкина С. А., Байков В. В. Принципы патоморфологической дифференциальной диагностики миелодиспластических синдромов. Клиническая онкогематология 2015;8(1):62–8.Della Porta M. G., Malcovati L., Boveri E. et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009;27(5):754–62. DOI:10.1200/JCO.2008.18.2246. PMID: 19103730.Kokhno A. V., Parovichnikova E. N., Savchenko V. G. Myelodysplastic syndrome. Klinicheskaya gerontologiya = Clinical gerontology 2009;15(3):33–46. (In Russ.).Кохно А. В., Паровичникова Е. Н., Савченко В. Г. Миелодиспластический синдром. Клиническая геронтология 2009;15(3):33–46.Kokhno A. V., Pimenova M. A., Parovichnikova E. N. et al. Detection of hidden karyotype anomalies in myelodysplastic syndrome. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(1):25–8 (In Russ.).Кохно А. В., Пименова М. А., Паровичникова Е. Н. и др. Выявление скрытых аномалий кариотипа при миелодиспластическом синдроме. Гематология и трансфузиология 2014;59(1):25–8.Valent P., Horny H. P., Bennett J. M. et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007;31(6):727–36. DOI: 10.1016/j.leukres.2006.11.009. PMID: 17257673.Loken M. R., van de Loosdrecht A., Ogata K. et al. Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 2008;32(1):5–17. DOI: 10.1016/j.leukres.2007.04.020. PMID: 17576013.Porwit A., van de Loosdrecht A. A., Bettelheim P. et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014;28(9):1793–8. DOI: 10.1038/leu.2014.191. PMID: 24919805.Westers T. M., Ireland R., Kern W. et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012;26(7):1730–41. DOI: 10.1038/leu.2012.30. PMID: 22307178.van de Loosdrecht A. A., Alhan C., Bene M. C. et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94(8):1124–34. DOI: 10.3324/haematol.2009.005801. PMID: 19546437.Aanei C. M., Picot T., Tavernier E. et al. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Front Oncol 2016;6:161. DOI: 10.3389/fonc.2016.00161. PMID: 27446807.Ogata K., Kishikawa Y., Satoh C. et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006;108(3):1037–44. DOI: 10.1182/blood-2005‑12‑4916. PMID: 16574954.van de Loosdrecht A. A., Westers T. M. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw 2013;11(7):892–902. PMID: 23847222.Bellos F., Kern W. Flow cytometry in the diagnosis of myelodysplastic syndromes (MDS) and the value of myeloid nuclear differentiation antigen (MNDA). Cytometry B Clin Cytom 2014;92(3): 200–6. DOI: 10.1002/cytob.21190. PMID: 25258054.Matarraz S., López A., Barrena S. et al. The immunophenotype of different immature, myeloid and B-cell lineagecommitted CD34+ hematopoietic cells allows discrimination between normal/ reactive and myelodysplastic syndrome precursors. Leukemia 2008;22(6):1175– 83. DOI: 10.1038/leu.2008.49. PMID: 18337765.Chabannon C., Wood P., Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992;149(6):2110–3. PMID: 1381397.Tien H. F., Wang C. H. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 1998;31(1–2):93–8. DOI: 10.3109/10428199809057588. PMID: 9720718.Ogata K., Nakamura K., Yokose N. et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100(12):3887–96. DOI: 10.1182/blood-2002‑01‑0222. PMID: 12393641.Jorgensen J. L., Chen S. S. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S49–53. DOI: 10.1016/j.clml.2011.03.023. PMID: 22035748.Jaso J. M., Wang S. A., Jorgensen J. L., Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant 2014;49(9):1129–38. DOI: 10.1038/bmt.2014.99. PMID: 24842529.van de Loosdrecht A. A., Westers T. M., Westra A. H. et al. Identification of distinct prognostic subgroups in lowand intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008;111(3):1067–77. DOI: 10.1182/blood-2007‑07‑098764. PMID: 17971483.Davis B. H., Foucar K., Szczarkowski W. et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997;30(5):249–63. PMID: 9383099.Moon H. W., Huh J. W., Lee M. et al. Immunophenotypic Features of Granulocytes, Monocytes, and Blasts in Myelodysplastic Syndromes. Korean J Lab Med 2010;30(2):97. DOI: 10.3343/kjlm.2010.30.2.97. PMID: 20445324.Gong P., Metrebian F., Dulau-Florea A. et al. Aberrant expression of CD56 on granulocytes and monocytes in myeloproliferative neoplasm. J Hematop 2013;6(3):127–34. DOI: 10.1007/s12308‑013‑0190-z.Kussick S. J., Wood B. L. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003;127(9):1140–7. DOI: 10.1043/1543–2165(2003) 127<1140:UCFCTI>2.0.CO;2. PMID: 12946231.Stetler-Stevenson M., Arthur D. C., Jabbour N. et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98(4):979–87. PMID: 11493442.Chung J. W., Park C. J., Cha C. H. et al. A combination of CD15/CD10, CD64/ CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome. Ann Clin Lab Sci 2012;42(3):271–80. PMID: 22964615.Lorand-Metze I., Ribeiro E., Lima C. S.P. et al. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007;31(2):147–55. DOI: 10.1016/j.leukres.2006.04.010. PMID: 16750852.Stachurski D., Smith B.R., Pozdnyakova O. et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008;32(2):215–24. DOI: 10.1016/j.leukres.2007.06.012. PMID: 17675229.van de Vyver A., Visser A. Decreased CD10 expression in the bone marrow neutrophils of HIV positive patients. Mediterr J Hematol Infect Dis 2010;2(3):e2010032. DOI: 10.4084/mjhid.2010.032. PMID: 21776338.Keerthivasan G., Mei Y., Zhao B. et al. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del (5q) MDS. Blood 2014;124(5):780–90. DOI: 10.1182/blood-2014‑01‑552463. PMID: 24891322.Cremers E. M. P., Westers T. M., Alhan C. et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica 2017;102(2):320–6. DOI: 10.3324/haematol.2016.147843. PMID: 27658438.Della Porta M. G., Picone C. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Mediterr J Hematol Infect Dis 2017;9(1):e2017017. DOI:10.4084/MJHID.2017.017. PMID: 28293405.Eidenschink Brodersen L., Menssen A. J., Wangen J. R. et al. Assessment of erythroid dysplasia by “difference from normal” in routine clinical flow cytometry workup. Cytometry B Clin Cytom 2015;88(2):125–35. DOI: 10.1002/cyto.b.21199. PMID: 25490867.Westers T. M., Cremers E. M.P., Oelschlaegel U. et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica 2017;102(2):308–19. DOI: 10.3324/haematol.2016.147835. PMID: 27758818.Wells D. A., Benesch M., Loken M. R. et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102(1):394–403. DOI: 10.1182/blood-2002‑09‑2768. PMID: 12649150.Chu S. C., Wang T. F., Li C. C. et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011;35(7):868–73. DOI: 10.1016/j.leukres.2011.02.016. PMID: 21397943.